January 2023

Brenus Pharma and InSphero receive €1.5 million in grants for the collaborative project “STC-1010”

2023-01-19T15:25:45+01:00

Brenus Pharma, a biotech company specialized in the development of [...]

Brenus Pharma and InSphero receive €1.5 million in grants for the collaborative project “STC-1010”2023-01-19T15:25:45+01:00

EverImmune launches phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer

2023-01-17T12:26:28+01:00

EverImmune supported by MATWIN in 2022 and interviewed by the [...]

EverImmune launches phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer2023-01-17T12:26:28+01:00

MPC Therapeutics announces completion of its CHF 1.5M seed-funding round to improve CAR-T cancer therapies.

2023-01-17T15:31:53+01:00

MPC Therapeutics supported by MATWIN in 2022 and awarded by MATWIN [...]

MPC Therapeutics announces completion of its CHF 1.5M seed-funding round to improve CAR-T cancer therapies.2023-01-17T15:31:53+01:00

Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers

2023-01-17T15:31:41+01:00

Smart Immune supported by MATWIN in 2022 and awarded “ Best Therapeutic Innovation” [...]

Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers2023-01-17T15:31:41+01:00

June 2022

Interview with Karine ROSSIGNOL, CEO Smart-Immune, MATWIN 2022 winner “Best therapeutic innovation”

2022-06-29T11:21:58+02:00

Introduce us SMARTIMMUNE in a few words Smart Immune, a [...]

Interview with Karine ROSSIGNOL, CEO Smart-Immune, MATWIN 2022 winner “Best therapeutic innovation”2022-06-29T11:21:58+02:00

May 2022

April 2021

Go to Top